{
    "nct_id": "NCT04083976",
    "official_title": "A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations",
    "inclusion_criteria": "* Histologic demonstration of an unresectable, locally advanced, or metastatic solid tumor malignancy with an fibroblast growth factor receptor (FGFR) mutation or FGFR gene fusion\n* Measurable disease\n* Participant must have received at least one prior line of systemic therapy in the advanced, unresectable, or metastatic setting; or is a child or adolescent participant with a newly-diagnosed solid tumor and no acceptable standard therapies\n* Documented progression of disease, defined as any progression that requires a change in treatment, prior to full study screening\nHealthy volunteers allowed\nMust have minimum age of 6 Years",
    "exclusion_criteria": "* Has had prior chemotherapy, targeted therapy, or treatment with an investigational anticancer agent within 15 days or less than or equal to (<=) 5 half-lives of the agent (whichever is longer) and up to a maximum of 30 days before the first dose of erdafitinib\n* The presence of FGFR gatekeeper and resistance mutations\n* Histologic demonstration of urothelial carcinoma\n* Hematologic malignancy (i.e., myeloid and lymphoid neoplasms\n* For non-small cell lung cancer participants only: pathogenic somatic mutations or gene fusions in the following genes: EGFR, ALK, ROS1, NTRK, BRAF V600E and KRAS\n* Active malignancies other than for disease requiring therapy",
    "miscellaneous_criteria": ""
}